A5075682238- Bone health and treatments
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer Cells and Metastasis
- Pharmacological Effects of Natural Compounds
- Bone Metabolism and Diseases
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Chromatography in Natural Products
- Ubiquitin and proteasome pathways
- Immune cells in cancer
- Biochemical and Molecular Research
- RNA Research and Splicing
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Ginseng Biological Effects and Applications
- RNA modifications and cancer
- Cytokine Signaling Pathways and Interactions
- Wnt/β-catenin signaling in development and cancer
- HIV Research and Treatment
- Cellular transport and secretion
Tsinghua University
2016-2025
Center for Life Sciences
2016-2019
Beijing Institute of Technology
2019
Immune checkpoint inhibitor (ICI) therapy is generating remarkable responses in individuals with cancer, but only a small portion of breast cancer respond well. Here we report that tumor-derived Jagged1 key regulator the tumor immune microenvironment. promotes tumorigenesis multiple spontaneous mammary models. Through Jagged1-induced Notch activation, cells increase expression and secretion cytokines to help recruit macrophages into Educated crosstalk tumor-infiltrating T inhibit cell...
Abstract The majority of patients with late-stage breast cancer develop distal bone metastases. microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation...
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S2 is related to Figure 5 (Olaparib-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Supplemental Figures 1-7</p>
<p>Supplemental Figures 1-7</p>